What is the current status of AstraZeneca and Daiichi Sankyo's negotiations with the UK's NICE over Enhertu reimbursement?

AstraZeneca and Daiichi Sankyo are nearing an agreement with the UK's National Institute for Health and Care Excellence (NICE) for their breast cancer drug Enhertu, following NICE's prior denial of coverage on grounds of cost-effectiveness for the NHS. An AstraZeneca spokesperson confirmed that discussions with NHS England and NICE are ongoing to identify a solution enabling access to Enhertu for HER2-low metastatic breast cancer patients in England, Wales, and Northern Ireland, though no details on the progress or terms were disclosed.

Why did NICE initially reject Enhertu, and what recent developments have renewed hope for its UK reimbursement?

NICE initially denied coverage for Enhertu because it deemed the drug not cost-effective for the state-backed National Health Service. AstraZeneca CEO Pascal Soriot stated in April that changes to Britain's cost-effectiveness methodology have created hope that Enhertu could gain reimbursement at a price acceptable to the company—though still below U.S. price levels—indicating that methodological updates, rather than just price concessions, are key to resolving the impasse.

AstraZeneca, Daiichi near UK pricing deal for breast cancer drug, Bloomberg News reports

ChemBrief

AstraZeneca, Daiichi near UK pricing deal for breast cancer drug, Bloomberg News reports — ChemBrief Topics

AstraZeneca, Daiichi near UK pricing deal for breast cancer drug, Bloomberg News reports

FAQ